Pharmacokinetics and Safety of DWJ1451 in Healthy Adults

Daewoong Pharmaceutical

Status and phase: Unknown; Phase 1

Conditions: Healthy

Treatments: Drug: DWJ1451

Study type: Interventional

Funder types: Industry

Identifiers

NCT04819932

DW_DWJ1451102

Details and patient eligibility

About

Amlodipine, olmesartan, total ezetimibe, rosuvastatin AUCt, Cmax

Enrollment: 64 estimated patients

Sex: All

Ages: 19 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 19 to 55 years
• Healthy Adult

Exclusion criteria

• Non-Healthy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

64 participants in 2 patient groups

group1

Experimental group

Description:

subject take DWC202008 and DWC2020091 on a fasted condition, and after wash out period, take DWJ1451 with on a fasted condition

Treatment:

Drug: DWJ1451

group2

Experimental group

Description:

subject take DWJ1451 on a fasted condition, and after wash out period, take DWC202008 and DWC202009 with on a fasted condition

Treatment:

Drug: DWJ1451